Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events

References

• Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202–7. doi:10.1038/s41588-018-0312-8.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 June;9(6):e002435. doi:10.1136/jitc-2021-002435.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec;39(36):4073–126. doi:10.1200/JCO.21.01440.
   PubMed Web of Science ®Google Scholar
• Ludi Y, Peiwei C, Jie Y, Xianqun F. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1):298–307. doi:10.20892/j.issn.2095-3941.2020.0559.
   PubMed Web of Science ®Google Scholar
• Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22(5):581–3. doi:10.1016/S1470-2045(21)00155-8.
   PubMed Web of Science ®Google Scholar
• Chen YW, Tucker MD, Beckermann KE, Iams WT, Rini BI, Johnson DB. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Sep;155:291–3. doi:10.1016/j.ejca.2021.07.017.
   PubMed Web of Science ®Google Scholar
• Valachis A, Rosén C, Koliadi A, Digkas E, Gustavsson A, Nearchou A, Ullenhag GJ. Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors. Oncoimmunology. 2021;10(1):1886725. doi:10.1080/2162402X.2021.1886725.
   PubMed Web of Science ®Google Scholar
• Calabrese L, Mariette X. The evolving role of the rheumatologist in the management of immune-related adverse events (irAes) caused by cancer immunotherapy. Ann Rheum Dis. 2018 Feb;77(2):162–4. doi:10.1136/annrheumdis-2017-212061.
   PubMed Web of Science ®Google Scholar
• Michot J, Ragou P, Carbonnel F, Champiat S, Voisin A-L, Mateus C, Lambotte O, Annereau M. Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication. J Immunother (Hagerstown, Md: 1997). 2018;41(2):84–5. doi:10.1097/CJI.0000000000000202.
   PubMed Web of Science ®Google Scholar
• Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer. 2016 Sep;99:148–50. doi:10.1016/j.lungcan.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y, Shi M, Liao W, Huang N. Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis. Front Pharmacol. 2022;13:817662. doi:10.3389/fphar.2022.817662.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol. 2022;13:955701. doi:10.3389/fphar.2022.955701.
   PubMedGoogle Scholar
• Wu L, Tsang VHM, Sasson SC, Menzies AM, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE. Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside. Front Endocrinol (Lausanne). 2021;12:764138. doi:10.3389/fendo.2021.764138.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang H, Zhou L, Li W, Yang L, Li W, Li K, Liu X. Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management. Front Oncol. 2021;11:627612. doi:10.3389/fonc.2021.627612.
   PubMed Web of Science ®Google Scholar
• Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG. et al. Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2023 Oct;72(10):3217–28. doi:10.1007/s00262-023-03489-1.
   PubMed Web of Science ®Google Scholar
• Brest P, Mograbi B, Hofman P, Milano G. COVID-19 vaccination and cancer immunotherapy: should they stick together? Br J Cancer. 2022 Jan;126(1):1–3. doi:10.1038/s41416-021-01618-0.
   PubMed Web of Science ®Google Scholar
• Keam B, Kang C, Jun K, Moon SM, Suh KJ, Lee D-W, Ock C-Y, Kim M, Choi Y, Lim Y. et al. Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. Clin Infect Dis. 2020;71(2):422–5. doi:10.1093/cid/ciz1092.
   PubMed Web of Science ®Google Scholar
• Lewis A, Annika F, Scott TCS, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J. et al. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat Med. 2021;27(8):1362–6. doi:10.1038/s41591-021-01387-6.
   PubMed Web of Science ®Google Scholar
• Chang Kyung K, Hang-Rae K, Kyoung-Ho S, Keam B, Choi SJ, Choe PG, Kim ES, Kim NJ, Kim YJ, Park WB. et al. Cell-mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. J Infect Dis. 2020;222(11):1902–9. doi:10.1093/infdis/jiaa291.
   PubMed Web of Science ®Google Scholar
• Trapani D, Curigliano G. COVID-19 vaccines in patients with cancer. Lancet Oncol. 2021 June;22(6):738–9. doi:10.1016/S1470-2045(21)00250-3.
   PubMed Web of Science ®Google Scholar